QuantiFERON-TB Gold PLUS versus QuantiFERON- TB Gold In-Tube test for diagnosing tuberculosis infection

Kim, Soo Han; Jo, Kyung‐Wook; Shim, Tae Sun

doi:10.3904/kjim.2019.002

Cited by 20 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…QuantiFERON-TB Plus (QFT-Plus) is the new version of the QFT-Gold In-Tube. Compared to the QFT-Gold In-Tube containing antigens optimized to stimulate CD4 + T cells, QFT-Plus contains new antigens optimized for both CD4 + and CD8 + T cell stimulation [18]. QFT-Plus has potential to indicate recent infection and disease activity.…”

Section: Quantiferon-tb Plusmentioning

confidence: 99%

Latent tuberculosis infection: recent progress and challenges in South Korea

Jeon

2020

Korean J Intern Med

View full text Add to dashboard Cite

Management of latent tuberculosis infection (LTBI) is a critical element in the elimination of tuberculosis (TB). However, the low positive predictive value of the current diagnostic tests and the low acceptance and completion rate of the isoniazid-based regimen are major barriers to the implementation and scale-up of programmatic management of LTBI. In the past decade, there has been some progress in the conception, diagnosis, and treatment of LTBI. LTBI is now understood as a dynamic spectrum rather than the traditional binary distinction between active and latent TB. New insight into LTBI has led to a renewed interest in incipient TB, which would be a potential target for developing new diagnostics and therapeutics of LTBI. Recent studies showed that host transcriptomic signatures could be a potential biomarker for incipient TB. The new shorter rifamycin-based regimens have shown comparable efficacy, but better completion rate and safety compared to the isoniazid-based regimen. In South Korea, LTBI management has been expanded and integrated into key elements of the National Tuberculosis Control Program. For the programmatic approach to LTBI management, the following challenges need to be addressed; target group selection, treatment-related interventions, monitoring and surveillance system, and extending the plan for vulnerable groups.

show abstract

Section: Quantiferon-tb Plusmentioning

confidence: 99%

Latent tuberculosis infection: recent progress and challenges in South Korea

Jeon

2020

Korean J Intern Med

View full text Add to dashboard Cite

show abstract

“…This unexpected result might have been due to the small number of patients in the high-risk TB infection group and/or the presence of recent LTBI-infected subjects in the low-risk TB infection group owing to casual contact with active TB patients in South Korea. Kim et al [5] concluded that two QFT-TB IGRAs have comparable performance, but the results could not confirm the diagnostic advantage of QFT-PLUS over QFT-GIT.…”

mentioning

confidence: 95%

“…In the latest issue of the Korean Journal of Internal Medicine, Kim et al [5] reported a comparative evaluation of QFT-PLUS and QFT-GIT for the diagnosis of TB infection in South Korea. In their study, QFT-PLUS and QFT-GIT had highly comparable results for TB infection diagnosis: 91.2% agreement and a Cohen's κ of 0.807.…”

mentioning

confidence: 99%

“…It has been suggested that a greater response to TB2 than TB1 would be associated with an increased mycobacterial load and recent TB infection [7]. However, according to Kim et al [5]…”

mentioning

confidence: 99%

“…In summary, although it was difficult to differentiate between the TB1 and TB2 antigen response based on whether the patients have a recent TB infection or immunocompromised status due to the small number of patients, Kim et al [5] suggested that the performance of QFT-PLUS is comparable to that of QFT-GIT in South Korea. Other predictive biomarkers and/or diagnostic methods are needed to identify LTBI patients at high risk of developing active TB.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Successful transition to the QFT-PLUS assay, but more is needed for diagnosis of latent tuberculosis infection

Lee

Kang

2020

Korean J Intern Med

View full text Add to dashboard Cite

Prevalence of indeterminate tuberculosis interferon‐gamma release assays in COVID‐19 patients: Systematic review and meta‐analysis

Ben Tekaya,

Jerbi,

Ben Sassi

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Background and AimsThe reliability of interferon‐gamma‐release‐assays (IGRAs) for tuberculosis (TB) testing in coronavirus disease 2019 (COVID‐19) patients is unknown. This study aimed to systematically review the prevalence of indeterminate TB‐IGRA following SARS‐CoV‐2 infection or vaccination and to review associated factors.MethodsThis systematic literature review was guided according to the PRISMA guidelines by searching PubMed, Scopus, Web of Science, Clinicalkey, and Cochrane Library. Studies reporting results of TB‐IGRA tests (QuantiFERON [QFT]‐TB, T‐SPOT.TB) in COVID‐19 patients or vaccines were included. The random effects model was used to assess the prevalence of indeterminate IGRA results. Heterogeneity was evaluated using the Τ2 and 95% predictive interval.ResultsOf the 273 citations screened, 12 articles were included in the final analysis including a total of 2107 patients. The overall pooled effect size proportion of indeterminate QFT‐TB results, estimated in eight studies using the QFT‐TB Plus assay, was 0.26 (95% CI: 0.205−0.324, Τ2 = 0.158). The mean true effect size was 0.26 (95% predictive interval: [0.110−0.500]). A subgroup analysis was not undertaken due to the small number of studies. Indeterminate QFT‐TB rates were associated with COVID‐19 severity, steroid treatment, inflammation‐related parameters, neutrophilia, and lymphopenia.ConclusionIndeterminate QFT‐TB results in COVID‐19 patients occur in almost one‐quarter of tests performed. Further studies are needed to assess associated factors.

show abstract

QuantiFERON-TB Gold PLUS versus QuantiFERON- TB Gold In-Tube test for diagnosing tuberculosis infection

Cited by 20 publications

References 30 publications

Latent tuberculosis infection: recent progress and challenges in South Korea

Latent tuberculosis infection: recent progress and challenges in South Korea

Successful transition to the QFT-PLUS assay, but more is needed for diagnosis of latent tuberculosis infection

Prevalence of indeterminate tuberculosis interferon‐gamma release assays in COVID‐19 patients: Systematic review and meta‐analysis

Contact Info

Product

Resources

About